More News

05 Aug 2017 Mallinckrodt To Acquire InfaCare Pharmaceutical Corporation And Stannsoporfin, Its Proprietary Therapy In Late-Stage Development For Treatment Of Newborns At Risk For Developing Severe Jaundice
04 Aug 2017 Avelas Biosciences Doses First Patient in Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
04 Aug 2017 Bristol-Myers Squibb to Acquire IFM Therapeutics to Strengthen Oncology Pipeline Focus on Innate Immunity
03 Aug 2017 Takeda and Molecular Templates Announce Multi-Target Research and Licensing Collaboration to Develop Next-Generation Oncology Therapies
03 Aug 2017 Evotec and Fraunhofer IME-SP Sign Strategic Collaboration on IPSC Technology
02 Aug 2017 Takeda and Cardurion Pharmaceuticals Launch Cardiovascular Development Partnership
01 Aug 2017 Cellectar Biosciences Signs Collaboration with Avicenna Oncology to Develop New PDCs for Solid Tumors
01 Aug 2017 Isogenica Announces New Licence Agreement with Takeda
31 Jul 2017 InVivo Therapeutics Announces Updates on the INSPIRE Study
31 Jul 2017 Loxo Oncology Announces Acquisition of Highly Selective, Reversible BTK Inhibitor Program
31 Jul 2017 LabCorp to Acquire Chiltern for Approximately $1.2 Billion in Cash, Advancing Its Leadership in Drug Development
31 Jul 2017 Generex Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with AE37 in Patients with Triple-Negative Breast Cancer
31 Jul 2017 Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types
31 Jul 2017 Evotec to Acquire Aptuit, Expanding Leadership in External Innovation
29 Jul 2017 CytRx Corporation Announces Global Strategic License With NantCell Inc. For Aldoxorubicin, An Albumin Mediated Chemotherapeutic
29 Jul 2017 Servier licenses GLPG1972 in osteoarthritis from Galapagos
27 Jul 2017 Arbutus Announces Conclusion of LNP License Agreement with Alexion
27 Jul 2017 Proteros enters into new research collaboration with Johnson & Johnson Innovation on sub-class of epigenetic targets
27 Jul 2017 Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates
27 Jul 2017 Complix Announces Expanded Strategic Oncology Collaboration with MSD to Develop Cell-Penetrating Alphabodies
27 Jul 2017 Bavarian Nordic Announces Agreement with Janssen for the Development of Vaccine Regimens against HIV-1 and Hepatitis B
27 Jul 2017 Evotec Expands Collaboration with Storm Therapeutics on Its RNA Epigenetics Platform
27 Jul 2017 Tesaro and Takeda enter into exclusive licensing agreement to develop and commercialize novel cancer therapy niraparib in Japan
27 Jul 2017 AstraZeneca and Merck establish strategic oncology collaboration
25 Jul 2017 Frontier Biotech licenses 3BNC117, a novel broad-spectrum HIV neutralizing antibody

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing